Barinthus Biotherapeutics plc annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Barinthus Biotherapeutics plc Depreciation & Amortization Growth & History (BRNS)
Barinthus Biotherapeutics plc's depreciation and amortization was $5.8M for fiscal 2025.
View full Barinthus Biotherapeutics plc company overviewBarinthus Biotherapeutics plc annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.8M | $45,000 | +0.78% |
| 2024 | 2024-12-31 | $5.8M | $371,000 | +6.83% |
| 2023 | 2023-12-31 | $5.4M | $1.1M | +25.58% |
| 2022 | 2022-12-31 | $4.3M | $3.7M | +618.11% |
| 2021 | 2021-12-31 | $602,000 | $394,000 | +189.42% |
| 2020 | 2020-12-31 | $208,000 | — | — |
Barinthus Biotherapeutics plc quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $820,000 | −$1.2M | −59.02% |
| Q1 2026 | 2026-03-31 | $856,000 | −$1.2M | −57.92% |
| Q4 2025 | 2025-12-31 | $909,000 | — | — |
| Q3 2025 | 2025-09-30 | $901,000 | −$574,000 | −38.92% |
| Q2 2025 | 2025-06-30 | $2.0M | $534,000 | +36.40% |
| Q1 2025 | 2025-03-31 | $2.0M | $604,000 | +42.24% |
| Q3 2024 | 2024-09-30 | $1.5M | $1,000 | +0.07% |
| Q2 2024 | 2024-06-30 | $1.5M | $168,000 | +12.93% |
| Q1 2024 | 2024-03-31 | $1.4M | $209,000 | +17.12% |
| Q3 2023 | 2023-09-30 | $1.5M | $286,000 | +24.07% |
| Q2 2023 | 2023-06-30 | $1.3M | $307,000 | +30.95% |
| Q1 2023 | 2023-03-31 | $1.2M | $255,000 | +26.40% |
| Q3 2022 | 2022-09-30 | $1.2M | $1.1M | +1297.65% |
| Q2 2022 | 2022-06-30 | $992,000 | $888,000 | +853.85% |
| Q1 2022 | 2022-03-31 | $966,000 | $874,000 | +950.00% |
| Q3 2021 | 2021-09-30 | $85,000 | $30,000 | +54.55% |
| Q2 2021 | 2021-06-30 | $104,000 | $56,000 | +116.67% |
| Q1 2021 | 2021-03-31 | $92,000 | $43,000 | +87.76% |
| Q3 2020 | 2020-09-30 | $55,000 | — | — |
| Q2 2020 | 2020-06-30 | $48,000 | — | — |
| Q1 2020 | 2020-03-31 | $49,000 | — | — |
Barinthus Biotherapeutics plc depreciation and amortization trends
Over the last five fiscal years, Barinthus Biotherapeutics plc's depreciation and amortization increased from $208,000 to $5.8M, a change of $5.6M. The latest reported quarter, Q2 2026, shows $820,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Barinthus Biotherapeutics plc source filings ↗